These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 24752277

  • 1. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, Jo Siu W, Pillai R.
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [Abstract] [Full Text] [Related]

  • 2. Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.
    Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y.
    PLoS One; 2016 Jul; 11(7):e0159661. PubMed ID: 27441843
    [Abstract] [Full Text] [Related]

  • 3. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M, Sugimoto N, Kawabata H, Yamakawa E, Kodera N, Pillai R, Tatsumi Y.
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [Abstract] [Full Text] [Related]

  • 4. Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis.
    Lee BC, Pangeni R, Na J, Koo KT, Park JW.
    Drug Deliv; 2019 Dec; 26(1):1167-1177. PubMed ID: 31738083
    [Abstract] [Full Text] [Related]

  • 5. Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.
    Monti D, Mazzantini D, Tampucci S, Vecchione A, Celandroni F, Burgalassi S, Ghelardi E.
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332076
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.
    Kubota-Ishida N, Takei-Masuda N, Kaneda K, Nagira Y, Chikada T, Nomoto M, Tabata Y, Takahata S, Maebashi K, Hui X, Maibach HI.
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084749
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic efficacy of topically applied KP-103 against experimental tinea unguium in guinea pigs in comparison with amorolfine and terbinafine.
    Tatsumi Y, Yokoo M, Senda H, Kakehi K.
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3797-801. PubMed ID: 12435679
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis.
    Tabata Y, Takei-Masuda N, Kubota N, Takahata S, Ohyama M, Kaneda K, Iida M, Maebashi K.
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1035-9. PubMed ID: 26643333
    [Abstract] [Full Text] [Related]

  • 10. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
    Kircik LH.
    J Drugs Dermatol; 2014 Dec; 13(12):1457-61. PubMed ID: 25607788
    [Abstract] [Full Text] [Related]

  • 11. Efinaconazole (Jublia) for the treatment of onychomycosis.
    Gupta AK, Simpson FC.
    Expert Rev Anti Infect Ther; 2014 Jul; 12(7):743-52. PubMed ID: 24850511
    [Abstract] [Full Text] [Related]

  • 12. Efinaconazole solution 10%: topical antifungal therapy for toenail onychomycosis.
    Tosti A.
    Cutis; 2013 Oct; 92(4):203-8. PubMed ID: 24195094
    [Abstract] [Full Text] [Related]

  • 13. How effective is efinaconazole in the management of onychomycosis?
    Gupta AK, Cernea M.
    Expert Opin Pharmacother; 2016 Oct; 17(4):611-8. PubMed ID: 26809447
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Comparison of Characteristics of Two Topical Therapeutic Agents for Onychomycosis].
    Shimamura T, Miyamae A, Imai A, Hirayanagi K, Iwanaga T, Kubota N, Shibuya K.
    Med Mycol J; 2016 Oct; 57(4):J141-J147. PubMed ID: 27904059
    [Abstract] [Full Text] [Related]

  • 16. Efinaconazole topical solution, 10%: the development of a new topical treatment for toenail onychomycosis.
    Pollak RA.
    J Am Podiatr Med Assoc; 2014 Nov; 104(6):568-73. PubMed ID: 25514267
    [Abstract] [Full Text] [Related]

  • 17. Efinaconazole in Onychomycosis.
    Gupta AK, Talukder M.
    Am J Clin Dermatol; 2022 Mar; 23(2):207-218. PubMed ID: 34902110
    [Abstract] [Full Text] [Related]

  • 18. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model.
    Nakamura A, Hirakawa S, Nagai H, Inagaki K.
    Med Mycol; 2021 Mar 04; 59(3):289-295. PubMed ID: 33539539
    [Abstract] [Full Text] [Related]

  • 19. Efinaconazole: a new topical treatment for onychomycosis.
    Gupta AK, Simpson FC.
    Skin Therapy Lett; 2014 Mar 04; 19(1):1-4. PubMed ID: 24570290
    [Abstract] [Full Text] [Related]

  • 20. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space.
    Elewski BE, Pollak RA, Pillai R, Olin JT.
    J Drugs Dermatol; 2014 Nov 04; 13(11):1394-8. PubMed ID: 25607708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.